Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jennifer Castro

Nurse Practitioner, Gerontology Bradenton, FL Nurse Practitioner

NPI 1841651015 CMS profile 10725969

5985 Silver Falls Run Ste 200, Bradenton, FL 34211

Open in the dashboard

General payments

$9,660

443 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Castro of Bradenton, FL is reported in the CMS Open Payments database as having received $9,660 across 443 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,534 107
2024 General $2,786 127
2023 General $1,269 56
2022 General $1,877 83
2021 General $1,194 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Castro
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Jennifer Castro were reported at $2,534. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Jennifer Castro Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,194 $133 $44–$396 $132
2022 $1,877 $142 $48–$452 $149
2023 $1,269 $158 $53–$482 $160
2024 $2,786 $171 $55–$533 $164
2025 $2,534 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Incyte Corporation $745 29 payments
  2. Merck Sharp & Dohme Corporation $663 30 payments
  3. AbbVie, Inc. $532 25 payments
  4. Novartis Pharmaceuticals Corporation $523 26 payments
  5. AstraZeneca Pharmaceuticals LP $521 26 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $520 22 payments
  7. Daiichi Sankyo Inc. $503 18 payments
  8. Pfizer Inc. $432 21 payments
  9. Celgene Corporation $284 10 payments
  10. E.R. Squibb & Sons, L.L.C. $265 14 payments
  11. Other $4,673 222 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,320 438 payments
  2. Education $340 5 payments
Products named General payments · program years 2021–2025
  1. KEYTRUDA $526 23 payments
  2. JAKAFI $478 23 payments
  3. ENHERTU $475 17 payments
  4. LYNPARZA $295 12 payments
  5. MONJUVI $248 13 payments
  6. OPDIVO $224 12 payments
  7. Sylvant $210 1 payment
  8. NINLARO $208 11 payments
  9. IMBRUVICA $206 9 payments
  10. RYBELSUS $200 14 payments
  11. Other $9,075 455 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

443 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record